Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2024

Open Access 01-12-2024 | Prediabetes | Research

The association between the triglyceride–glucose index and the risk of cardiovascular disease in US population aged ≤ 65 years with prediabetes or diabetes: a population-based study

Authors: Chang Liu, Dan Liang

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Background

The relationship between the triglyceride–glucose (TyG) index and the risk of cardiovascular disease (CVD) in the U.S. population under 65 years of age with diabetes or prediabetes is unknown. The purpose of this study was to investigate the relationship between baseline TyG index and CVD risk in U.S. patients under 65 years of age with diabetes or prediabetes.

Methods

We used data from the 2003–2018 National Health and Nutrition Examination Survey (NHANES). Multivariate regression analysis models were constructed to explore the relationship between baseline TyG index and CVD risk. Nonlinear correlations were explored using restricted cubic splines. Subgroup analysis and interaction tests were also conducted.

Results

The study enrolled a total of 4340 participants with diabetes or pre-diabetes, with a mean TyG index of 9.02 ± 0.02. The overall average prevalence of CVD was 10.38%. Participants in the higher TyG quartiles showed high rates of CVD (Quartile 1: 7.35%; Quartile 2: 10.04%; Quartile 3: 10.71%; Quartile 4: 13.65%). For CVD, a possible association between the TyG index and the risk of CVD was observed. Our findings suggested a linear association between the TyG index and the risk of CVD. The results revealed a U-shaped relationship between the TyG index and both the risk of CVD (P nonlinear = 0.02583) and CHF (P nonlinear = 0.0208) in individuals with diabetes. Subgroup analysis and the interaction term indicated that there was no significant difference among different stratifications. Our study also revealed a positive association between the TyG index and comorbid MetS in the U.S. population under 65 years of age with prediabetes or diabetes.

Conclusions

A higher TyG index was linked to an increased likelihood of CVD in the U.S. population aged ≤ 65 years with prediabetes and diabetes. Besides, TyG index assessment will contribute to more convenient and effective screening of high-risk individuals in patients with MetS. Future studies should explore whether interventions targeting the TyG index may improve clinical outcomes in these patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93–621.PubMedCrossRef Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93–621.PubMedCrossRef
2.
go back to reference Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15(4):215–29.PubMedCrossRef Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15(4):215–29.PubMedCrossRef
3.
go back to reference Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.PubMedPubMedCentralCrossRef Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.PubMedPubMedCentralCrossRef
4.
go back to reference Roth GA, Mensah GA, Fuster V. The global burden of cardiovascular diseases and risks: a compass for global action. J Am Coll Cardiol. 2020;76(25):2980–1.PubMedCrossRef Roth GA, Mensah GA, Fuster V. The global burden of cardiovascular diseases and risks: a compass for global action. J Am Coll Cardiol. 2020;76(25):2980–1.PubMedCrossRef
5.
go back to reference Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818–27.PubMedCrossRef Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818–27.PubMedCrossRef
6.
go back to reference Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr. 2019;13(2):1449–55.PubMedCrossRef Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr. 2019;13(2):1449–55.PubMedCrossRef
7.
go back to reference Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119: 154766.PubMedCrossRef Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119: 154766.PubMedCrossRef
8.
go back to reference Huang R, Wang Z, Chen J, Bao X, Xu N, Guo S, et al. Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart failure. Cardiovasc Diabetol. 2022;21(1):88.PubMedPubMedCentralCrossRef Huang R, Wang Z, Chen J, Bao X, Xu N, Guo S, et al. Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart failure. Cardiovasc Diabetol. 2022;21(1):88.PubMedPubMedCentralCrossRef
9.
go back to reference Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.PubMedCrossRef Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.PubMedCrossRef
10.
go back to reference Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med. 2002;19(7):527–34.PubMedCrossRef Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med. 2002;19(7):527–34.PubMedCrossRef
11.
go back to reference Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab. 2003;17(3):305–22.PubMedCrossRef Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab. 2003;17(3):305–22.PubMedCrossRef
12.
go back to reference Park HM, Lee HS, Lee YJ, Lee JH. The triglyceride–glucose index is a more powerful surrogate marker for predicting the prevalence and incidence of type 2 diabetes mellitus than the homeostatic model assessment of insulin resistance. Diabetes Res Clin Pract. 2021;180: 109042.PubMedCrossRef Park HM, Lee HS, Lee YJ, Lee JH. The triglyceride–glucose index is a more powerful surrogate marker for predicting the prevalence and incidence of type 2 diabetes mellitus than the homeostatic model assessment of insulin resistance. Diabetes Res Clin Pract. 2021;180: 109042.PubMedCrossRef
13.
go back to reference Liu X, Tan Z, Huang Y, Zhao H, Liu M, Yu P, et al. Relationship between the triglyceride–glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):124.PubMedPubMedCentralCrossRef Liu X, Tan Z, Huang Y, Zhao H, Liu M, Yu P, et al. Relationship between the triglyceride–glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):124.PubMedPubMedCentralCrossRef
14.
go back to reference Che B, Zhong C, Zhang R, Pu L, Zhao T, Zhang Y, et al. Triglyceride–glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data. Cardiovasc Diabetol. 2023;22(1):34.PubMedPubMedCentralCrossRef Che B, Zhong C, Zhang R, Pu L, Zhao T, Zhang Y, et al. Triglyceride–glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data. Cardiovasc Diabetol. 2023;22(1):34.PubMedPubMedCentralCrossRef
15.
go back to reference Huang Z, Ding X, Yue Q, Wang X, Chen Z, Cai Z, et al. Triglyceride–glucose index trajectory and stroke incidence in patients with hypertension: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):141.PubMedPubMedCentralCrossRef Huang Z, Ding X, Yue Q, Wang X, Chen Z, Cai Z, et al. Triglyceride–glucose index trajectory and stroke incidence in patients with hypertension: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):141.PubMedPubMedCentralCrossRef
16.
go back to reference Lu YW, Chang CC, Chou RH, Tsai YL, Liu LK, Chen LK, et al. Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan longitudinal aging study. Cardiovasc Diabetol. 2021;20(1):206.PubMedPubMedCentralCrossRef Lu YW, Chang CC, Chou RH, Tsai YL, Liu LK, Chen LK, et al. Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan longitudinal aging study. Cardiovasc Diabetol. 2021;20(1):206.PubMedPubMedCentralCrossRef
17.
go back to reference Wang X, Ji X, Yu J, Wang F. Correlation between TyG index and coronary atherosclerosis assessed by CCTA in elderly male patients: a cross-sectional study. Diabetol Metab Syndr. 2023;15(1):176.PubMedPubMedCentralCrossRef Wang X, Ji X, Yu J, Wang F. Correlation between TyG index and coronary atherosclerosis assessed by CCTA in elderly male patients: a cross-sectional study. Diabetol Metab Syndr. 2023;15(1):176.PubMedPubMedCentralCrossRef
18.
go back to reference Rivière B, Jaussent A, Macioce V, Faure S, Builles N, Lefebvre P, et al. The triglycerides and glucose (TyG) index: a new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients. Diabetes Metab. 2022;48(4): 101345.PubMedCrossRef Rivière B, Jaussent A, Macioce V, Faure S, Builles N, Lefebvre P, et al. The triglycerides and glucose (TyG) index: a new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients. Diabetes Metab. 2022;48(4): 101345.PubMedCrossRef
19.
go back to reference Liu L, Wu Z, Zhuang Y, Zhang Y, Cui H, Lu F, et al. Association of triglyceride–glucose index and traditional risk factors with cardiovascular disease among non-diabetic population: a 10-year prospective cohort study. Cardiovasc Diabetol. 2022;21(1):256.PubMedPubMedCentralCrossRef Liu L, Wu Z, Zhuang Y, Zhang Y, Cui H, Lu F, et al. Association of triglyceride–glucose index and traditional risk factors with cardiovascular disease among non-diabetic population: a 10-year prospective cohort study. Cardiovasc Diabetol. 2022;21(1):256.PubMedPubMedCentralCrossRef
20.
go back to reference Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83.PubMedPubMedCentralCrossRef Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83.PubMedPubMedCentralCrossRef
21.
go back to reference Pan Y, Zhong S, Zhou K, Tian Z, Chen F, Liu Z, et al. Association between diabetes complications and the triglyceride–glucose index in hospitalized patients with type 2 diabetes. J Diabetes Res. 2021;2021:8757996.PubMedPubMedCentralCrossRef Pan Y, Zhong S, Zhou K, Tian Z, Chen F, Liu Z, et al. Association between diabetes complications and the triglyceride–glucose index in hospitalized patients with type 2 diabetes. J Diabetes Res. 2021;2021:8757996.PubMedPubMedCentralCrossRef
22.
go back to reference Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314(10):1021–9.PubMedCrossRef Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314(10):1021–9.PubMedCrossRef
23.
go back to reference Zou X, Zhou X, Zhu Z, Ji L. Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. Lancet Diabetes Endocrinol. 2019;7(1):9–11.PubMedCrossRef Zou X, Zhou X, Zhu Z, Ji L. Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. Lancet Diabetes Endocrinol. 2019;7(1):9–11.PubMedCrossRef
24.
go back to reference Expert Panel on Detection Evaluation. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.CrossRef Expert Panel on Detection Evaluation. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.CrossRef
25.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Crit Pathw Cardiol. 2005;4(4):198–203.PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Crit Pathw Cardiol. 2005;4(4):198–203.PubMedCrossRef
26.
go back to reference Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016. NCHS Data Brief. 2017;289:1–8. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016. NCHS Data Brief. 2017;289:1–8.
27.
go back to reference Liu Q, Si F, Liu Z, Wu Y, Yu J. Association between triglyceride–glucose index and risk of cardiovascular disease among postmenopausal women. Cardiovasc Diabetol. 2023;22(1):21.PubMedPubMedCentralCrossRef Liu Q, Si F, Liu Z, Wu Y, Yu J. Association between triglyceride–glucose index and risk of cardiovascular disease among postmenopausal women. Cardiovasc Diabetol. 2023;22(1):21.PubMedPubMedCentralCrossRef
28.
go back to reference Cai XL, Xiang YF, Chen XF, Lin XQ, Lin BT, Zhou GY, et al. Prognostic value of triglyceride glucose index in population at high cardiovascular disease risk. Cardiovasc Diabetol. 2023;22(1):198.PubMedPubMedCentralCrossRef Cai XL, Xiang YF, Chen XF, Lin XQ, Lin BT, Zhou GY, et al. Prognostic value of triglyceride glucose index in population at high cardiovascular disease risk. Cardiovasc Diabetol. 2023;22(1):198.PubMedPubMedCentralCrossRef
29.
go back to reference Yu H, Tao L, Li YG, Yang L, Liu D, Wang Y, et al. Association between triglyceride–glucose index trajectories and carotid atherosclerosis progression. Cardiovasc Diabetol. 2023;22(1):130.PubMedPubMedCentralCrossRef Yu H, Tao L, Li YG, Yang L, Liu D, Wang Y, et al. Association between triglyceride–glucose index trajectories and carotid atherosclerosis progression. Cardiovasc Diabetol. 2023;22(1):130.PubMedPubMedCentralCrossRef
30.
go back to reference Jin JL, Cao YX, Wu LG, You XD, Guo YL, Wu NQ, et al. Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. J Thorac Dis. 2018;10(11):6137–46.PubMedPubMedCentralCrossRef Jin JL, Cao YX, Wu LG, You XD, Guo YL, Wu NQ, et al. Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. J Thorac Dis. 2018;10(11):6137–46.PubMedPubMedCentralCrossRef
31.
go back to reference Wan Y, Zhang Z, Ling Y, Cui H, Tao Z, Pei J, et al. Association of triglyceride–glucose index with cardiovascular disease among a general population: a prospective cohort study. Diabetol Metab Syndr. 2023;15(1):204.PubMedPubMedCentralCrossRef Wan Y, Zhang Z, Ling Y, Cui H, Tao Z, Pei J, et al. Association of triglyceride–glucose index with cardiovascular disease among a general population: a prospective cohort study. Diabetol Metab Syndr. 2023;15(1):204.PubMedPubMedCentralCrossRef
32.
go back to reference Jiang X, Tu J, Chen S, Zhang Y, Qiu W, Chen K, et al. Association of triglyceride–glucose index with the prevalence of cardiovascular disease in malnourished/non-malnourished patients: a large cross-sectional study. Front Cardiovasc Med. 2023;10:1306415.PubMedPubMedCentralCrossRef Jiang X, Tu J, Chen S, Zhang Y, Qiu W, Chen K, et al. Association of triglyceride–glucose index with the prevalence of cardiovascular disease in malnourished/non-malnourished patients: a large cross-sectional study. Front Cardiovasc Med. 2023;10:1306415.PubMedPubMedCentralCrossRef
33.
go back to reference Li S, Guo B, Chen H, Shi Z, Li Y, Tian Q, et al. The role of the triglyceride (triacylglycerol) glucose index in the development of cardiovascular events: a retrospective cohort analysis. Sci Rep. 2019;9(1):7320.PubMedPubMedCentralCrossRef Li S, Guo B, Chen H, Shi Z, Li Y, Tian Q, et al. The role of the triglyceride (triacylglycerol) glucose index in the development of cardiovascular events: a retrospective cohort analysis. Sci Rep. 2019;9(1):7320.PubMedPubMedCentralCrossRef
34.
go back to reference Hong S, Han K, Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study. BMC Med. 2020;18(1):361.PubMedPubMedCentralCrossRef Hong S, Han K, Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study. BMC Med. 2020;18(1):361.PubMedPubMedCentralCrossRef
35.
go back to reference Ye Z, Xie E, Jiao S, Gao Y, Li P, Tu Y, et al. Triglyceride glucose index exacerbates the risk of future cardiovascular disease due to diabetes: evidence from the China Health and Retirement Longitudinal Survey (CHARLS). BMC Cardiovasc Disord. 2022;22(1):236.PubMedPubMedCentralCrossRef Ye Z, Xie E, Jiao S, Gao Y, Li P, Tu Y, et al. Triglyceride glucose index exacerbates the risk of future cardiovascular disease due to diabetes: evidence from the China Health and Retirement Longitudinal Survey (CHARLS). BMC Cardiovasc Disord. 2022;22(1):236.PubMedPubMedCentralCrossRef
36.
go back to reference Zhao M, Xiao M, Tan Q, Lu F. Triglyceride glucose index as a predictor of mortality in middle-aged and elderly patients with type 2 diabetes in the US. Sci Rep. 2023;13(1):16478.PubMedPubMedCentralCrossRef Zhao M, Xiao M, Tan Q, Lu F. Triglyceride glucose index as a predictor of mortality in middle-aged and elderly patients with type 2 diabetes in the US. Sci Rep. 2023;13(1):16478.PubMedPubMedCentralCrossRef
37.
go back to reference Barzegar N, Tohidi M, Hasheminia M, Azizi F, Hadaegh F. The impact of triglyceride–glucose index on incident cardiovascular events during 16 years of follow-up: Tehran lipid and glucose study. Cardiovasc Diabetol. 2020;19(1):155.PubMedPubMedCentralCrossRef Barzegar N, Tohidi M, Hasheminia M, Azizi F, Hadaegh F. The impact of triglyceride–glucose index on incident cardiovascular events during 16 years of follow-up: Tehran lipid and glucose study. Cardiovasc Diabetol. 2020;19(1):155.PubMedPubMedCentralCrossRef
38.
go back to reference Wang H, He S, Wang J, An Y, Wang X, Li G, et al. Hyperinsulinemia and plasma glucose level independently associated with all-cause and cardiovascular mortality in Chinese people without diabetes-A post-hoc analysis of the 30-year follow-up of Da Qing diabetes and IGT study. Diabetes Res Clin Pract. 2023;195: 110199.PubMedCrossRef Wang H, He S, Wang J, An Y, Wang X, Li G, et al. Hyperinsulinemia and plasma glucose level independently associated with all-cause and cardiovascular mortality in Chinese people without diabetes-A post-hoc analysis of the 30-year follow-up of Da Qing diabetes and IGT study. Diabetes Res Clin Pract. 2023;195: 110199.PubMedCrossRef
39.
go back to reference Zhang Q, Xiao S, Jiao X, Shen Y. The triglyceride–glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: evidence from NHANES 2001–2018. Cardiovasc Diabetol. 2023;22(1):279.PubMedPubMedCentralCrossRef Zhang Q, Xiao S, Jiao X, Shen Y. The triglyceride–glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: evidence from NHANES 2001–2018. Cardiovasc Diabetol. 2023;22(1):279.PubMedPubMedCentralCrossRef
40.
go back to reference Galassetti P, Davis SN. Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia. Clin Sci (Lond). 2000;99(5):351–62.PubMedCrossRef Galassetti P, Davis SN. Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia. Clin Sci (Lond). 2000;99(5):351–62.PubMedCrossRef
41.
go back to reference da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited. Can J Cardiol. 2020;36(5):671–82.PubMedCrossRef da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited. Can J Cardiol. 2020;36(5):671–82.PubMedCrossRef
42.
go back to reference Molina MN, Ferder L, Manucha W. Emerging role of nitric oxide and heat shock proteins in insulin resistance. Curr Hypertens Rep. 2016;18(1):1.PubMedCrossRef Molina MN, Ferder L, Manucha W. Emerging role of nitric oxide and heat shock proteins in insulin resistance. Curr Hypertens Rep. 2016;18(1):1.PubMedCrossRef
43.
go back to reference Janus A, Szahidewicz-Krupska E, Mazur G, Doroszko A. Insulin resistance and endothelial dysfunction constitute a common therapeutic target in cardiometabolic disorders. Mediat Inflamm. 2016;2016:3634948.CrossRef Janus A, Szahidewicz-Krupska E, Mazur G, Doroszko A. Insulin resistance and endothelial dysfunction constitute a common therapeutic target in cardiometabolic disorders. Mediat Inflamm. 2016;2016:3634948.CrossRef
44.
go back to reference Brillante DG, O’Sullivan AJ, Howes LG. Arterial stiffness in insulin resistance: the role of nitric oxide and angiotensin II receptors. Vasc Health Risk Manag. 2009;5(1):73–8.PubMedPubMedCentral Brillante DG, O’Sullivan AJ, Howes LG. Arterial stiffness in insulin resistance: the role of nitric oxide and angiotensin II receptors. Vasc Health Risk Manag. 2009;5(1):73–8.PubMedPubMedCentral
45.
go back to reference Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A. Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection. Pflugers Arch. 2022;474(1):83–98.PubMedCrossRef Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A. Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection. Pflugers Arch. 2022;474(1):83–98.PubMedCrossRef
47.
go back to reference Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovasc Res. 2017;113(4):389–98.PubMedCrossRef Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovasc Res. 2017;113(4):389–98.PubMedCrossRef
48.
49.
50.
go back to reference Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.PubMedPubMedCentralCrossRef Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.PubMedPubMedCentralCrossRef
51.
go back to reference Li T, Wang P, Wang X, Liu Z, Zhang Z, Zhang Y, et al. Inflammation and insulin resistance in diabetic chronic coronary syndrome patients. Nutrients. 2023;15(12):2808.PubMedPubMedCentralCrossRef Li T, Wang P, Wang X, Liu Z, Zhang Z, Zhang Y, et al. Inflammation and insulin resistance in diabetic chronic coronary syndrome patients. Nutrients. 2023;15(12):2808.PubMedPubMedCentralCrossRef
52.
go back to reference Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. J Int Med Res. 2023;51(3):3000605231164548.PubMedCrossRef Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. J Int Med Res. 2023;51(3):3000605231164548.PubMedCrossRef
54.
go back to reference Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol. 2006;48(12):2531–8.PubMedCrossRef Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol. 2006;48(12):2531–8.PubMedCrossRef
55.
go back to reference Kelem A, Adane T, Shiferaw E. Insulin resistance-induced platelet hyperactivity and a potential biomarker role of platelet parameters: a narrative review. Diabetes Metab Syndr Obes. 2023;16:2843–53.PubMedPubMedCentralCrossRef Kelem A, Adane T, Shiferaw E. Insulin resistance-induced platelet hyperactivity and a potential biomarker role of platelet parameters: a narrative review. Diabetes Metab Syndr Obes. 2023;16:2843–53.PubMedPubMedCentralCrossRef
58.
go back to reference Issa BG, Hanna FW. Insulin resistance, the metabolic syndrome and risk of cardiovascular disease: a complex story. Curr Opin Lipidol. 2003;14(4):405–7.PubMedCrossRef Issa BG, Hanna FW. Insulin resistance, the metabolic syndrome and risk of cardiovascular disease: a complex story. Curr Opin Lipidol. 2003;14(4):405–7.PubMedCrossRef
59.
go back to reference Gupta A, Gupta V. Metabolic syndrome: What are the risks for humans? Biosci Trends. 2010;4(5):204–12.PubMed Gupta A, Gupta V. Metabolic syndrome: What are the risks for humans? Biosci Trends. 2010;4(5):204–12.PubMed
60.
go back to reference Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003;20(4):255–68.PubMedCrossRef Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003;20(4):255–68.PubMedCrossRef
61.
go back to reference Gluvic Z, Zaric B, Resanovic I, Obradovic M, Mitrovic A, Radak D, et al. Link between metabolic syndrome and insulin resistance. Curr Vasc Pharmacol. 2017;15(1):30–9.PubMedCrossRef Gluvic Z, Zaric B, Resanovic I, Obradovic M, Mitrovic A, Radak D, et al. Link between metabolic syndrome and insulin resistance. Curr Vasc Pharmacol. 2017;15(1):30–9.PubMedCrossRef
62.
go back to reference Kang SW, Kim SK, Kim YS, Park MS. Risk prediction of the metabolic syndrome using TyG Index and SNPs: a 10-year longitudinal prospective cohort study. Mol Cell Biochem. 2023;478(1):39–45.PubMedCrossRef Kang SW, Kim SK, Kim YS, Park MS. Risk prediction of the metabolic syndrome using TyG Index and SNPs: a 10-year longitudinal prospective cohort study. Mol Cell Biochem. 2023;478(1):39–45.PubMedCrossRef
63.
go back to reference Primo D, Izaola O, de Luis DA. Triglyceride–glucose index cutoff point is an accurate marker for predicting the prevalence of metabolic syndrome in obese Caucasian subjects. Ann Nutr Metab. 2023;79(2):238–45.PubMedCrossRef Primo D, Izaola O, de Luis DA. Triglyceride–glucose index cutoff point is an accurate marker for predicting the prevalence of metabolic syndrome in obese Caucasian subjects. Ann Nutr Metab. 2023;79(2):238–45.PubMedCrossRef
64.
go back to reference Mylonas KS, Sarantis P, Kapelouzou A, Karamouzis MV, Kapetanakis EI, Kontzoglou K, et al. Mechanosensitive stem-cell genes and Klotho in atherosclerotic aortas: regulating spatially deranged expression patterns using colchicine regimens. J Clin Med. 2022;11(21):6465.PubMedPubMedCentralCrossRef Mylonas KS, Sarantis P, Kapelouzou A, Karamouzis MV, Kapetanakis EI, Kontzoglou K, et al. Mechanosensitive stem-cell genes and Klotho in atherosclerotic aortas: regulating spatially deranged expression patterns using colchicine regimens. J Clin Med. 2022;11(21):6465.PubMedPubMedCentralCrossRef
65.
go back to reference Ray L, Ravichandran K, Nanda SK. Comparison of lipid accumulation product index with body mass index and waist circumference as a predictor of metabolic syndrome in Indian population. Metab Syndr Relat Disord. 2018;16(5):240–5.PubMedCrossRef Ray L, Ravichandran K, Nanda SK. Comparison of lipid accumulation product index with body mass index and waist circumference as a predictor of metabolic syndrome in Indian population. Metab Syndr Relat Disord. 2018;16(5):240–5.PubMedCrossRef
Metadata
Title
The association between the triglyceride–glucose index and the risk of cardiovascular disease in US population aged ≤ 65 years with prediabetes or diabetes: a population-based study
Authors
Chang Liu
Dan Liang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-024-02261-8

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine